Trastuzumab biosimilar - Allergan/Amgen

Drug Profile

Trastuzumab biosimilar - Allergan/Amgen

Alternative Names: ABP-980

Latest Information Update: 02 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Synthon
  • Developer Allergan; Amgen
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action ERBB 2 receptor antagonists; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Breast cancer
  • Phase Unknown Gastric cancer

Most Recent Events

  • 31 Jul 2017 Preregistration for Breast cancer in USA (IV)
  • 25 Jul 2017 Amgen plans to make a regulatory submission to the US FDA for trastuzumab biosimilar for Cancer
  • 19 Jul 2017 CTP ACTRN12614000400662 - trial completion date updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top